NewcelX sharpens focus on Type 1 Diabetes cell therapy, expands SAB and leadership.

NewcelX, a clinical-stage cell therapy company, has released an updated corporate presentation highlighting its focus on Type 1 Diabetes cell therapy and recent scientific progress. The presentation introduces new members to the company's Scientific Advisory Board and leadership team, reinforcing its strategic direction. NewcelX plans to participate in investor and partnering conferences, including BIO-Europe Spring in Lisbon.